
Practical considerations when using anti-amyloid antibodies for the treatment of Alzheimer’s disease
Anti-amyloid antibodies are the first disease-modifying therapies for Alzheimer's disease (AD), with two agents—lecanemab and donanemab—now fully approved by the U.S. Food and Drug Administration (FDA).
This podcast features experts Paulo Caramelli, MD, PhD, Federal University of Minas Gerais, Belo Horizonte, Brazil, Stephen P. Salloway, MD, MS, Butler Hospital & Warren Alpert Medical School of Brown University, Providence, RI, Suzanne Schindler, MD, PhD, Washington University School of Medicine in St. Louis, St. Louis, MO, and Dorota Religa, MD, PhD, Karolinska Institutet, Solna, Sweden, who discuss the practical considerations when using these therapies.
The discussion explores pivotal clinical trial findings, appropriate use recommendations, the management of amyloid-related imaging abnormalities (ARIA), and patients who may not be eligible for these treatments.
More episodes from "VJDementia Podcast"



Don't miss an episode of “VJDementia Podcast” and subscribe to it in the GetPodcast app.








